Back to Hematology
Hematologyv2014Evidence-Based

National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)

Predicts survival in patients with diffuse large B-cell lymphoma (DLBCL) using age, LDH levels, extranodal involvement, Ann Arbor stage, and ECOG performance status. Developed for the rituximab era with enhanced prognostic discrimination.

Clinical Input Parameters

years
Range: 18 — 120 years
ratio
Range: 0.1 — 20 ratio
Range: 0 — 4
Clinical Assessment
Awaiting Parameters
nccn ipi score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

NCCN-IPI Score = Age points + LDH points + Extranodal sites (1 if yes) + Ann Arbor stage (1 if III/IV) + ECOG status (1 if ≥2) Age: ≤40 (0), >40-60 (1), >60-75 (2), >75 (3) LDH: Normal (0), >1-3× ULN (1), ≥3× ULN (2)

Clinical Pearls & Practice Notes

  • Developed specifically for patients treated in the rituximab era
  • Extranodal sites refer to involvement of bone marrow, CNS, liver/GI tract, or lung only
  • Provides better discrimination than conventional IPI for low and high-risk patients
  • Maximum score is 8 points, minimum is 0 points
  • Should be used at initial diagnosis before treatment initiation

Evidence & Literature Citations

  1. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 6;123(6):837-42.
  2. Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020 Jun 4;135(23):2041-2048.
  3. Gleeson M, Hawkes EA, Peckitt C, Wotherspoon A, Attygalle A, Sharma B, et al. Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. Br J Haematol. 2021 Feb;192(6):1015-1019.

Score Interpretation Ranges

Low0 – 1 pts

Low risk

Low-Intermediate2 – 3 pts

Low-intermediate risk

High-Intermediate4 – 5 pts

High-intermediate risk

High6 – 8 pts

High risk

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.